Ocugen, Inc. (OCGN) Gets Provisional, Priority LARTA Nod for OCU400 in The Bahamas

Ocugen received Provisional Approval and Priority Designation under The Bahamas' LARTA to provide OCU400 for retinitis pigmentosa via an Early Access Program, aiming to treat the first patient within 90 days following full LARTA approval.Material DetailsContext by AI AnalystThis is a strategic regu…